Teva completes acquisition of Allergan generics armTeva Pharmaceutical completes $40 billion acquisition of the generics arm of rival Allergan.
Teva's $40.5 Billion deal expected to go through next weekIsraeli pharmaceutical company wins regulatory approval for acquisition of Allergan, conditional upon giving up some of its products.
Is the next Google being developed in Israel?Experts disagree as to whether the tech world in Israel is capable of maturing to the level where a tech giant such as Google can exist.
Israeli Pharma Giant Teva Buys Botox's Allergan$40.5 billion purchase solidifies Teva as world leader in generic drugs, after $40.1 billion bid for rival Mylan meets resistance.
Subsidiary's Crime Costs Israeli Teva $1.2 BillionIsraeli pharma giant to pay for illegal monopoly 'pay for delay' move made by company Cephalon - before Teva acquired it.
Shimon Peres to Advise Teva Pharmaceuticals in Lucrative DealConsulting job to the tune of $10,000 per month reportedly on the table; details have not been finalized.
Israeli Pharma Company Teva Looks to Become Global Giant$40 billion acquisition of US company would launch Teva to unprecedented size - but will its bid be accepted?
Pharmaceutical Giant Teva's Chairman to ResignChairman Phillip Frost's announcement the latest in a string of abrupt changes in major Israeli company.
Teva Setback: Competitors Can Sell Copaxone, Court SaysA U.S. Supreme Court Justice gave a green light for competitors of Teva to sell generic versions of multiple sclerosis drug Copaxone.
Erez Vigodman Named New Teva CEOTeva on Thursday named Erez Vigodman, 54, as new CEO of the company, after last October's controversial resignation of Dr. Jeremy Levin.
Pfizer Settles with Teva on Generic ViagraTeva will pay Pfizer a royalty for a license to produce its generic version, from late 2017.
Teva Brings 'Captive Profits' Home, Gets Big Tax BreakTeva said Monday that it would return tens billions of shekels to Israel from abroad, and pay a tax bill of nearly three billion shekels.
CEO of Teva Pharmaceuticals Steps DownJeremy Levin resigns from the pharmaceutical giant amid tensions in the company
Teva Promises: Layoffs Will be Coordinated with HistadrutAfter meeting with Histadrut chairman, pharmaceutical giant promises it will coordinate layoff plans.
Lapid 'Dissatisfied' with Teva LayoffsFinance Minister says he has spoken to Teva's CEO and asked him to reduce the number of employees the company lays off.
Teva Laying Off 5,000 EmployeesPharmaceutical firm will reduce global manpower by 10%; 700-800 layoffs expected in Israel.
American Jew to Head TevaAmerican Jew Dr. Jeremy Levin was named new CEO for Teva Pharmaceuticals Monday, when Shlomo Yanai announced he is stepping down.
Former CEO of Teva Pharmaceuticals Dies at 79Eli Hurvitz, who served as CEO of Teva Pharmaceutical Industries until 2002, passes away from a serious illness.
Israeli Drug: No More Insulin Injections?Two Israeli-based firms try out a peptide aimed at stopping Type 1 diabetes at its source and eliminate the need for insulin injections.
New Cure for Lymphoma Passes Phase II Clinical TrialA new treatment for lymphoma, a type of cancer, has passed its Phase II clinical trial. CT-011 is produced by CureTech, a Teva company.
Teva, Appealing Whopping Verdict in US, Opens Giant CenterIsrael’s Teva Pharmaceutical Industries Ltd., the world’s largest maker of generic drugs, has dedicated its new, $100 million distribution center.
FDA Approves Two Teva Pharmaceuticals Generics, Stocks GainTeva Pharmaceuticals enjoys the approval of two new generics by the US Food and Drug Administration, stocks rise.
Teva Acquires German Generic Maker RatiopharmIsraeli pharmaceutical giant Teva has won the bid to acquire German generic drug maker Ratiopharm for $4.9 billion.
Israel’s TEVA a Headache for Drug Firms, Rx for InvestorsIsraeli-based TEVA has been called a juggernaut, copy-cat and an 800-pound ape. It makes generic drugs, lots of them, and money – lots of it.
Teva Partners on New Prostate, Lung Cancer TreatmentIsraeli pharmaceutical giant Teva has signed a deal to invest $60 million in a new cancer-fighting drug to fight prostate and lung cancer.